About us –

Our mission is to transform the lives of patients through best-in-class microbiome medicines

Our process of developing full-spectrum icrobiome medicines

Values

Our company values are central to our mission and guide everything we do…

 

Ambitious for patients

We put the needs of patients first in everything we do. We stay focussed on delivering what matters most, faster and better.

Innovative

We are open to abandoning old ideas and acting upon new evidence as it is presented, always focussed on continuous improvement and pushing scientific boundaries.

Collaborative

We instinctively seek to work with others to enable excellent outcomes and create strong communities within the workplace, displaying interest and passion in everything we do.

Resilient

We are focused and orientate our energies towards delivering on our commitments, always thrive in adversity and continuously adapt for growth.

Accountable

We set clear expectations, take ownership of objectives and hold ourselves and our teams accountable for the results we achieve.

Integrity

We are honest, transparent and always seek to do the right thing.

The EBX story

Our big moments

 

2017

EnteroBiotix incorporates

2018

Operations begin in Aberdeen, Scotland

2019

MHRA GMP license awarded for Aberdeen manufacturing facility

 

2021

$21m Series A investment announced with participation from an international group of investors

2022

Second manufacturing facility established and achieves MHRA GMP license

EnteroBiotix opens state-of-the-art site in Bellshill, Scotland

Collaboration announced with Imperial College London focused on the microbiome in cancer

2023

First patient dosed in Phase II clinical trial

Meet the team

Executive team

 

Dr James McIlroy
MBChB, BMedSci (Hons)

Chief Executive Officer

Dr James McIlroy founded EnteroBiotix after recognising the therapeutic potential of the microbiome with the vision of building one of world’s leading microbiome drug development companies. 

Chris Lea
CA

Chief Financial Officer & Company Secretary

Chris is a Chartered Accountant with extensive financial leadership experience, having successfully managed AIM-listed companies, which were later acquired by larger corporations.

 

Dr James Barnes
PhD

Chief Operating Officer

Dr James Barnes holds a Biomedical Science degree and PhD with extensive experience of strategic leadership in drug development and business operations.

Kimberley McAleney
PGD

Director of People

Kimberley has extensive experience in the design and successful execution of HR strategy, supporting fast-paced scaling businesses across a variety of industries, most recently in Biotechnology.

 

Board of Directors

 

Elmar Schnee
Executive Chairman

Elmar was previously a Member of the Executive Board of Merck KGaA and CEO of Merck Serono, and has held senior leadership roles at UCB and Sanofi. He currently serves as Chairman of the board of directors of Calliditas Therapeutics AG, ProCom Rx SA, Moleac Pte Ltd and Noorik Biopharmaceuticals

 

Dr James R. McIlroy
Chief Executive Officer

Dr James McIlroy founded EnteroBiotix after recognising the therapeutic potential of the microbiome with the vision of building one of world’s leading microbiome drug development companies.

 
 

Mark R. Bamforth
Investor Director

Mark Bamforth founded Arranta Bio to build the best-in-class microbiome CDMO, in May 2019. Arranta has process development and early clinical manufacturing in Florida and a late-stage manufacturing facility in Massachusetts. Previously, Bamforth founded Brammer Bio, a best-in-class viral vector contract development and manufacturing organization (CDMO) for cell and gene therapies. Brammer’s team grew from 110 in 2016 to over 600 in Florida and Massachusetts, at the time of its acquisition by Thermo Fisher Scientific in April 2019.

 

Iain Baird
Investor Director

Iain Baird is the principal of Development Solutions, a pharmaceutical consultancy firm focused on helping companies in Biological Pharmaceutical Development establish their Chemistry Manufacturing and Controls (CMC) capability.

 
 

Douglas Thomson
Investor Director

Douglas is founder and Chief Executive Officer of Pneumagen Limited. Founded in April 2016, Pneumagen is developing first-in-class products for the prevention and treatment of infectious disease.

 

David Lawrence
Independent Non-Executive Director

David is is an accomplished executive with over 30 years of experience in finance, M&A, business development and corporate strategy in the life sciences industry.

 

Find out more about our donor programme. Visit Number2.org